12th International Symposium
ADVANCED Ovarian Cancer
Optimal Therapy, Update
Valencia, 22nd February 2019

Organized by
Under the auspices of

www.valencia-ovariancancersymp.org

SCIENTIFIC COMMITTEE
Andrés Cervantes (ESMO, GEICO)
Antonio González (ESMO, GEICO)
Andrés Poveda (ESMO, GEICO)
Jan B. Vermorken (ESMO, GEICO)

ACCREDITATION
The programme of this event has been accredited with 6 ESMO-MORA category 1 points
Accreditation requested to the Spanish Authorities of Continuing Medical Education.

LANGUAGE
The official language of the symposium is English. Simultaneous translation into Spanish will be provided.

VENUE
Palacio de la Música “Iturbi”
Meeting Room
Paseo de la Alameda, 30 · 46023 Valencia, Spain

SYMPOSIUM SECRETARIAT
Alliance
C/ Monasterios de Suso y Yuso 34, 4-14-2 · 28049 Madrid
Phone: (+34) 91 372 02 03
email: aocsymp2019@doctaforum.com
Registration: www.valencia-ovariancancersymp.org

Alliance
AstraZeneca
Roche
TESARO

www.geicogroup.com

www.valencia-ovariancancersymp.org

The official language of the symposium is English. Simultaneous translation into Spanish will be provided.

SYMPOSIUM SECRETARIAT
Alliance
C/ Monasterios de Suso y Yuso 34, 4-14-2 · 28049 Madrid
Phone: (+34) 91 372 02 03
email: aocsymp2019@doctaforum.com
Registration: www.valencia-ovariancancersymp.org

Alliance
AstraZeneca
Roche
TESARO

www.geicogroup.com
SESSION 5: TREATMENT OF PRIMARY DISEASE
Chair: Antonio González, Clínica Universidad de Navarra, Madrid, Spain

8:35-8:55 How to manage lymph nodes in ovarian cancer in 2019
Philippe Harter, Kliniken Essen-Mitte, Essen, Germany

8:55-9:15 Can we predict who lives long with ovarian cancer?
Michael A. Bookman, Kaiser Permanente, Northern (CA), USA

9:15-9:35 Landscape of systemic therapy for ovarian cancer in 2019
Keiichi Fujiwara, Saitama Medical University International Medical Center, Saitama, Japan

9:35-9:55 Discussion
A1

9:55-10:25 Coffee Break

SESSION 2: TREATMENT OF RECURRENT DISEASE
Chair: Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Paris, France
Ana Oaknin, Vall d’Hebron University Hospital. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

11:15-11:35 Who needs surgery?
Jalid Sehouli, Charité University of Medicine, Berlin, Germany

11:35-11:55 Do all patients need systemic therapy?
Michael Friedlander, Royal Hospital for Women and Nelune Cancer Center, Sydney, Australia

11:55-12:15 Landscape of systemic therapy for recurrent ovarian cancer in 2019
Sandro Pignata, National Cancer Institute, Naples, Italy

12:15-12:35 Discussion
A1

12:35-13:05 Lunch

SESSION 3: TREATMENT OF RECURRENT DISEASE
Chair: Mansoor Mirza, Copenhagen University Hospital, Copenhagen, Denmark
Andres Redondo, Hospital Universitario La Paz, Madrid, Spain

17:00-17:20 Immunotherapy in Ovarian Cancer: Still promising?
Michael Piattoni, National Cancer Institute, Bethesda, MD, USA

17:20-17:40 New Strategies in Ovarian Cancer Treatment
Jalid Sehouli, Charité University of Medicine, Berlin, Germany

17:40-18:00 Remarks and Conclusions
Andres Poveda, Initia Oncology, Hospital Quironsalud, Valencia, Spain

REMINDERS AND CONCLUSIONS
17:40-18:00 Remarks and Conclusions
Brona Goss, University of Otago, Dunedin, New Zealand